keyword
MENU ▼
Read by QxMD icon Read
search

Reynaulds

keyword
https://www.readbyqxmd.com/read/28941580/immunoglobulins-benefits-and-risks-from-the-patient-s-point-of-view
#1
Bruno Revol, Laura Bickert, Françoise Sarrot-Reynauld, Benoit Allenet
Patients have to be informed about the risks and benefits of medicinal products derived from human plasma. No study has examined the patient's perspective yet. Our objective was to assess perceived benefits and risks of immunoglobulins administration from the patient's point of view. Thirty-four patients receiving subcutaneous or intravenous immunoglobulins for chronic disorders at a single university hospital were asked to complete a survey. Although the level of comfort was high, the results revealed variable and incomplete knowledge, in particular about the nature of the treatment...
July 31, 2017: Thérapie
https://www.readbyqxmd.com/read/28564695/efficacy-and-tolerance-of-anti-tumor-necrosis-factor-%C3%AE-agents-in-cutaneous-sarcoidosis-a-french-study-of-46-cases
#2
MULTICENTER STUDY
Valentine Heidelberger, Saskia Ingen-Housz-Oro, Alicia Marquet, Matthieu Mahevas, Didier Bessis, Laurence Bouillet, Frédéric Caux, Catherine Chapelon-Abric, Sébastien Debarbieux, Emmanuel Delaporte, Anne-Bénédicte Duval-Modeste, Olivier Fain, Pascal Joly, Sylvain Marchand-Adam, Jean-Benoît Monfort, Nicolas Noël, Thierry Passeron, Marc Ruivard, Françoise Sarrot-Reynauld, Denis Verrot, Diane Bouvry, Laurence Fardet, Olivier Chosidow, Pascal Sève, Dominique Valeyre
Importance: Evidence for the long-term efficacy and safety of anti-tumor necrosis factor α agents (anti-TNF) in treating cutaneous sarcoidosis is lacking. Objective: To determine the efficacy and safety of anti-TNF in treating cutaneous sarcoidosis in a large observational study. Design, Setting, and Participants: STAT (Sarcoidosis Treated with Anti-TNF) is a French retrospective and prospective multicenter observational database that receives data from teaching hospitals and referral centers, as well as several pneumology, dermatology, and internal medicine departments...
July 1, 2017: JAMA Dermatology
https://www.readbyqxmd.com/read/28392046/efficacy-and-safety-of-tumor-necrosis-factor-antagonists-in-refractory-sarcoidosis-a-multicenter-study-of-132-patients
#3
Yvan Jamilloux, Fleur Cohen-Aubart, Catherine Chapelon-Abric, Delphine Maucort-Boulch, Alicia Marquet, Laurent Pérard, Laurence Bouillet, Alban Deroux, Sébastien Abad, Philip Bielefeld, Diane Bouvry, Marc André, Nicolas Noel, Boris Bienvenu, Alice Proux, Sandra Vukusic, Bahram Bodaghi, Françoise Sarrot-Reynauld, Jean Iwaz, Zahir Amoura, Christiane Broussolle, Patrice Cacoub, David Saadoun, Dominique Valeyre, Pascal Sève
INTRODUCTION: The off-label use of TNF antagonists in refractory sarcoidosis is increasingly reported but data on their efficacy and safety are still insufficient. OBJECTIVE: To report on efficacy and safety of TNF antagonists in severe and refractory sarcoidosis. METHODS: Examination of retrospective demographic, clinical, therapeutic, and adverse event data on 132 sarcoidosis patients (58% women; mean (min-max) age = 45.5 (14-78) years) given TNF antagonists (mainly infliximab, 91%) and investigation of response-linked factors...
March 8, 2017: Seminars in Arthritis and Rheumatism
https://www.readbyqxmd.com/read/28355985/cessation-of-oral-anticoagulants-in-antiphospholipid-syndrome
#4
C Comarmond, P Jego, C Veyssier-Belot, I Marie, A Mekinian, A Elmaleh-Sachs, G Leroux, D Saadoun, E Oziol, T Fraisse, H Hyvernat, M-F Thiercein-Legrand, F Sarrot-Reynauld, N Ferreira-Maldent, M de Menthon, C Goujard, D Khau, Y Nguen, S Monnier, A Michon, B Castel, O Decaux, J-C Piette, P Cacoub
Objective To study the outcome of patients with antiphospholipid syndrome (APS) after oral anticoagulant treatment cessation. Methods We performed a retrospective study of patients with APS experiencing cessation of oral anticoagulant and enrolled in a French multicentre observational cohort between January 2014 and January 2016. The main outcome was the occurrence of recurrent thrombotic event after oral anticoagulation cessation. Results Forty four APS patients interrupted oral anticoagulation. The median age was 43 (27-56) years...
January 1, 2017: Lupus
https://www.readbyqxmd.com/read/27631981/association-between-the-presence-of-autoantibodies-targeting-ficolin-3-and-active-nephritis-in-patients-with-systemic-lupus-erythematosus
#5
MULTICENTER STUDY
Maëlle Plawecki, Elise Lheritier, Giovanna Clavarino, Noémie Jourde-Chiche, Saber Ouili, Stéphane Paul, Evelyne Gout, Françoise Sarrot-Reynauld, Nathalie Bardin, Pierre-Yves Boëlle, Laurent Chiche, Laurence Bouillet, Nicole M Thielens, Jean-Yves Cesbron, Chantal Dumestre-Pérard
Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by the production of multiple autoantibodies. Antibodies against Ficolin-3 were previously identified in the sera of some SLE patients, but their prevalence and significance have not been yet investigated. The aims of this study were to determine the prevalence of anti-ficolin-3 antibodies among SLE patients and to investigate their potential as diagnostic and/or prognostic biomarkers in SLE. In this retrospective study, sera from SLE patients (n = 165) were selected from a preexisting declared biological collection...
2016: PloS One
https://www.readbyqxmd.com/read/26209399/hepatitis-e-and-neuralgic-amyotrophy-five-cases-and-review-of-literature
#6
REVIEW
Anaïs Dartevel, Barbara Colombe, Annick Bosseray, Sylvie Larrat, Françoise Sarrot-Reynauld, Aude Belbezier, Emmeline Lagrange, Laurence Bouillet
Hepatitis E virus infection - mainly genotype 3 - is increasingly common in industrialized countries. Infection is usually asymptomatic, but cases of central or peripheral neurological symptoms with hepatitis E have been described. The most frequent is Guillain-Barre but somes cases of neuralgic amyotrophy have been described. In our center, since 2010, we have identified five cases of neuralgic amyotrophy associated with acute hepatitis E in immunocompetent patients. For all these patients, neuralgic amyotrophy was diagnosed with electromyogram and positive IgM for hepatitis E, and detectable HEV RNA in 4 of the cases...
August 2015: Journal of Clinical Virology: the Official Publication of the Pan American Society for Clinical Virology
https://www.readbyqxmd.com/read/25547160/isolated-flushes-without-permanent-fixed-or-other-skin-lesions-in-patients-with-systemic-mastocytosis-a-case-series-of-9-patients
#7
Emmanuel Lafont, Ludovic Lhermitte, Gandhi Damaj, Erinn Soucie, Stéphane Barete, Marie-Olivia Chandesris, Laure Cabaret, Isabelle Guichard, Isabelle Durieu, Frédérique Retornaz, Françoise Sarrot-Reynauld, Mohamed Hamidou, Julie Bruneau, Achille Aouba, Patrice Dubreuil, Olivier Lortholary, Vahid Asnafi, Olivier Hermine, Sophie Georgin-Lavialle
No abstract text is available yet for this article.
April 2015: European Journal of Dermatology: EJD
https://www.readbyqxmd.com/read/25117654/systemic-lupus-erythematosus-associated-acute-transverse-myelitis-manifestations-treatments-outcomes-and-prognostic-factors-in-20-patients
#8
MULTICENTER STUDY
J Saison, N Costedoat-Chalumeau, D Maucort-Boulch, J Iwaz, R Marignier, P Cacoub, D Vital-Durand, A Hot, J Tebib, O Aumaitre, N Schleinitz, F Sarrot-Reynauld, C Broussolle, P Sève
BACKGROUND: Transverse myelitis is a rare complication of systemic lupus erythematosus (SLE). This retrospective multicentre study identifies the prognostic factors in a relatively large patient series. PATIENTS AND METHODS: Twenty patients fulfilled the SLE criteria of the ACR classification and the Transverse Myelitis Consortium Working Group. A severe neurological flare was defined as muscle strength grade <3/5 in more than half the muscle groups at the motor neurological level...
January 2015: Lupus
https://www.readbyqxmd.com/read/25058083/autologous-hematopoietic-stem-cell-transplantation-vs-intravenous-pulse-cyclophosphamide-in-diffuse-cutaneous-systemic-sclerosis-a-randomized-clinical-trial
#9
RANDOMIZED CONTROLLED TRIAL
Jacob M van Laar, Dominique Farge, Jacob K Sont, Kamran Naraghi, Zora Marjanovic, Jérôme Larghero, Annemie J Schuerwegh, Erik W A Marijt, Madelon C Vonk, Anton V Schattenberg, Marco Matucci-Cerinic, Alexandre E Voskuyl, Arjan A van de Loosdrecht, Thomas Daikeler, Ina Kötter, Marc Schmalzing, Thierry Martin, Bruno Lioure, Stefan M Weiner, Alexander Kreuter, Christophe Deligny, Jean-Marc Durand, Paul Emery, Klaus P Machold, Francoise Sarrot-Reynauld, Klaus Warnatz, Daniel F P Adoue, Joël Constans, Hans-Peter Tony, Nicoletta Del Papa, Athanasios Fassas, Andrea Himsel, David Launay, Andrea Lo Monaco, Pierre Philippe, Isabelle Quéré, Éric Rich, Rene Westhovens, Bridget Griffiths, Riccardo Saccardi, Frank H van den Hoogen, Willem E Fibbe, Gérard Socié, Alois Gratwohl, Alan Tyndall
IMPORTANCE: High-dose immunosuppressive therapy and autologous hematopoietic stem cell transplantation (HSCT) have shown efficacy in systemic sclerosis in phase 1 and small phase 2 trials. OBJECTIVE: To compare efficacy and safety of HSCT vs 12 successive monthly intravenous pulses of cyclophosphamide. DESIGN, SETTING, AND PARTICIPANTS: The Autologous Stem Cell Transplantation International Scleroderma (ASTIS) trial, a phase 3, multicenter, randomized (1:1), open-label, parallel-group, clinical trial conducted in 10 countries at 29 centers with access to a European Group for Blood and Marrow Transplantation-registered transplant facility...
June 25, 2014: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/23833039/study-of-anti-m%C3%A3-llerian-hormone-and-its-relation-to-the-subsequent-probability-of-pregnancy-in-112-patients-with-systemic-lupus-erythematosus-exposed-or-not-to-cyclophosphamide
#10
RANDOMIZED CONTROLLED TRIAL
Nathalie Morel, Anne Bachelot, Zeina Chakhtoura, Pascale Ghillani-Dalbin, Zahir Amoura, Lionel Galicier, Olivier Aumaitre, Jean-Charles Piette, Jacques Pourrat, Du Boutin, Karim Sacre, Jean-Emmanuel Kahn, Pierre Duhaut, Dominique Farge, Camille Francès, Gaëlle Guettrot-Imbert, Jean-Robert Harlé, Olivier Lambotte, Véronique Le Guern, Damien Sène, Salim Trad, Elisabeth Vidal, Francoise Sarrot-Reynauld, Anne Gompel, Marie-Laure Tanguy, Philippe Touraine, Jean-Marc Lacorte, Nathalie Costedoat-Chalumeau
CONTEXT: Cyclophosphamide is used for renal and major extrarenal involvement in systemic lupus erythematosus (SLE) and is associated with a risk of premature ovarian failure. There are no data available about the relation between anti-Müllerian hormone (AMH) serum levels and the probability of subsequent pregnancy in SLE patients. OBJECTIVE: We analyzed AMH levels and the probability of pregnancy in SLE women exposed to cyclophosphamide. DESIGN AND SETTING: We conducted a matched cohort study in referral centers for SLE...
September 2013: Journal of Clinical Endocrinology and Metabolism
https://www.readbyqxmd.com/read/22079677/hematological-malignancy-associated-with-polymyositis-and-dermatomyositis
#11
REVIEW
I Marie, L Guillevin, J-F Menard, P Y Hatron, P Cherin, Z Amoura, P Cacoub, H Bachelez, A Buzyn, G Le Roux, J M Ziza, P Brice, J N Munck, F Sarrot-Reynauld, J C Piette, C Larroche
The aims of this present study were to: 1) assess the characteristics of hematological malignancies in polymyositis/polymyositis (PM/DM) patients; and 2) determine predictive variables of hematological malignancies in PM/DM patients. We retrospectively reviewed the medical records of 32 patients (14 PM, 18 DM) associated with hematological malignancies. In our 32 PM/DM patients, hematological malignancy was concurrently identified (18.8%) or occurred during the course of PM/DM (31.2%); although, PM/DM more often preceded hematological malignancy onset (50%)...
July 2012: Autoimmunity Reviews
https://www.readbyqxmd.com/read/20727624/-abdominal-pain-in-a-44-year-old-woman
#12
L Bouillet, D Fagedet, F Sarrot-Reynauld, C Massot, E Andrès
No abstract text is available yet for this article.
October 2010: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/20005023/-recurrent-hypoglycemia-in-a-68-year-old-man
#13
C Bossu Estour, M Guillaume, F Sarrot Reynauld, P E Rouge, L Bouillet, C Massot, L Fardet
No abstract text is available yet for this article.
March 2010: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/18520327/autoimmune-hemolytic-anemia-and-common-variable-immunodeficiency-a-case-control-study-of-18-patients
#14
Pascal Sève, Laure Bourdillon, Francoise Sarrot-Reynauld, Marc Ruivard, Rolland Jaussaud, Damien Bouhour, Bernard Bonotte, Martine Gardembas, Vincent Poindron, Marie-France Thiercelin, Christiane Broussolle, Eric Oksenhendler
To describe the main characteristics and treatment of autoimmune hemolytic anemia (AHA) in patients with common variable immunodeficiency (CVID), we analyzed data from 18 patients, 4 from an earlier study and 14 from the French DEF-I cohort on adult patients with primary hypogammaglobulinemia. To be included, patients had to have CVID and a previous history of AHA with a hemoglobin level < or =90 g/L at onset. To determine whether AHA is associated with a particular clinical phenotype of CVID, we conducted a case-control study from the DEF-I cohort...
May 2008: Medicine (Baltimore)
https://www.readbyqxmd.com/read/18050172/diagnostic-and-prognostic-relevance-of-neuromuscular-biopsy-in-primary-sj%C3%A3-gren-s-syndrome-related-neuropathy
#15
MULTICENTER STUDY
Benjamin Terrier, Catherine Lacroix, Loïc Guillevin, Pierre-Yves Hatron, Robin Dhote, François Maillot, Elisabeth Diot, Françoise Sarrot-Reynauld, Christelle Sordet, Odile Dubourg, Laurence Meyer, Xavier Mariette, Jacques-Eric Gottenberg et al.
OBJECTIVE: To evaluate the clinicobiologic presentation in patients with primary Sjögren's syndrome (SS)-related peripheral neuropathy, the histologic results of neuromuscular biopsy (NMB), and clinical outcome, and to identify prognostic factors. METHODS: We retrospectively studied clinical and biologic presentation of 40 patients with primary SS-related neuropathy who underwent NMB. Prognostic factors of clinical outcome were assessed by univariate and multivariate analysis...
December 15, 2007: Arthritis and Rheumatism
https://www.readbyqxmd.com/read/18050165/vasculitides-associated-with-malignancies-analysis-of-sixty-patients
#16
Olivier Fain, Mohamed Hamidou, Patrice Cacoub, Bertrand Godeau, Bertrand Wechsler, Jacques Pariès, Jérôme Stirnemann, Anne-Sophie Morin, Marc Gatfosse, Thomas Hanslik, Nadia Belmatoug, Olivier Blétry, Ramiro Cevallos, Isabelle Delevaux, Evelyne Fisher, Gilles Hayem, Gérard Kaplan, Claire Le Hello, Luc Mouthon, Claire Larroche, Véra Lemaire, Anne-Marie Piette, Jean-Charles Piette, Thierry Ponge, Xavier Puechal, Jérôme Rossert, Françoise Sarrot-Reynauld, Didier Sicard, Jean-Marc Ziza, Marcel-Francis Kahn, Loïc Guillevin
OBJECTIVE: To describe characteristics and outcomes of vasculitides associated with malignancies. METHODS: The requirement for inclusion in this retrospective, 10-year study was development of vasculitis in patients with a progressing malignancy. Malignancies secondary to immunosuppressants used to treat vasculitis were excluded. The main characteristics of vasculitides were analyzed and compared according to the type of malignancy. RESULTS: Sixty patients were included (male/female sex ratio 2...
December 15, 2007: Arthritis and Rheumatism
https://www.readbyqxmd.com/read/16207327/local-hyperemia-to-heating-is-impaired-in-secondary-raynaud-s-phenomenon
#17
COMPARATIVE STUDY
Aude Boignard, Muriel Salvat-Melis, Patrick H Carpentier, Christopher T Minson, Laurent Grange, Catherine Duc, Françoise Sarrot-Reynauld, Jean-Luc Cracowski
Accurate and sensitive measurement techniques are a key issue in the quantification of the microvascular and endothelial dysfunction in systemic sclerosis (SSc). Thermal hyperemia comprises two separate mechanisms: an initial peak that is axon reflex mediated; and a sustained plateau phase that is nitric oxide dependent. The main objective of our study was to test whether thermal hyperemia in patients with SSc differed from that in patients with primary Raynaud's phenomenon (RP) and healthy controls. In a first study, we enrolled 20 patients suffering from SSc, 20 patients with primary RP and 20 healthy volunteers...
2005: Arthritis Research & Therapy
https://www.readbyqxmd.com/read/16198895/systemic-mastocytosis-predictable-factors-of-poor-prognosis-present-at-the-onset-of-the-disease
#18
Katia Stankovic, Françoise Sarrot-Reynauld, Marie Puget, Christian Massot, Jacques Ninet, Bernard Lorcerie, Jean-Louis Dupond, Gilles Salles, Isabelle Durieu, Denis Vital Durand, Hugues Rousset
Systemic mastocytosis (SM) refers to a group of heterogeneous diseases that can be divided into indolent SM, for which prognosis is favorable, and malignant SM, which has a poor prognosis. While the diagnosis of SM is often a challenge since clinical and biological abnormalities are not specific, prognosis is even more difficult to predict. Thus, we aimed to highlight predictable factors in a cohort of 28 cases of SM. Among the 13 women and 15 men studied were 7 patients who had an aggressive form of SM that ultimately led to death in 3 of them...
October 2005: European Journal of Internal Medicine
https://www.readbyqxmd.com/read/15936480/-tuberous-sclerosis-without-mental-impairment-diagnosed-in-adulthood
#19
L Timotin, F Sarrot-Reynauld, S Lantuejoul, B Pasquier, C Massot, A Ashraf, F Borgel
INTRODUCTION: Tuberous sclerosis complex (TSC) is an autosomal dominant inherited phakomatosis, usually diagnosed in childhood and characterized by cutaneous and neurological tumors, the latter often leading to epilepsy and mental retardation. EXEGESIS: We report a case of TSC diagnosed in a 33-year-old man, without any known family history of phakomatosis, presenting with facial angiofibromas, hypomelanotic macules, a giant-cell astrocytoma and retinal phakomas without any mental impairment or epilepsy...
June 2005: La Revue de Médecine Interne
https://www.readbyqxmd.com/read/15798553/-therapeutic-intensification-and-autologous-stem-cell-transplantation-in-autoimmune-diseases
#20
REVIEW
Z Marjanovic, I Gerber, C Toledano, J Hen-Solal, R Damade, I de Saint-Cyr, F Sarrot-Reynauld, D Ilié, M Daneshpouy, N Mounier, M Ruivard, C Tyndall, E Vidal, I Quere, J-M Durand, J Constans, D Farge
THE PATHOPHYSIOLOGY of most autoimmune diseases is often poorly understood. EXPERIMENTAL CONSIDERATIONS and clinical experience suggest that high doses immunoablation followed by stem cell transplantation is a therapeutic option to consider for certain severe autoimmune disorders. THE CONCEPT OF RESTORING NORMAL IMMUNE REACTIVITY must in part br true since current results of 466 transplants (445 autologous, 21 allogeneic) patients suffering from various autoimmune diseases show a beneficial outcome in approximately 2/3 of the patients...
February 26, 2005: La Presse Médicale
keyword
keyword
57413
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"